Kornimate/medical-research-clean huggingface dataset:
study of endothelial cells in patients with hereditary haemorrhagic telangiectasia

Conditions: Telangiectasia, Hereditary Hemorrhagic

Summary: hereditary haemorrhagic telangiectasia (hht, also known as osler-weber-rendu syndrome) is an disease that leads to the development of dilated and fragile blood vessels. we propose to culture endothelial cells from patients with hht, to culture cells that express the proteins mutated in hht, namely endoglin and alk-1. we will study the properties of these cells which will involve their growth in different conditions and anticipate that dna, mrna and proteins will be extracted from these cells for study of cell responses and association with expression levels of endoglin and alk-1. we hypothesize that these cells which express "half-normal" endoglin or alk-1 will show altered protein synthetic differences when compared to normal white blood cells. we anticipate that that these findings may help to explain aspects of the hht disease phenotype.


Eligibility criteria:
inclusion criteria: * patients with hereditary haemorrhagic telangiectasia and family members exclusion criteria: * unable to provide informed consent
self-administered one-of-a kind approach to epilepsy therapy through a web-based music application

Conditions: Epilepsy; Refractory Epilepsy; Music

Summary: this is a prospective, placebo-controlled, double-blinded randomized study of self-administered auditory intervention in a naturalistic home environment.

this study aims to replicate and extend findings from prior electrophysiological studies that demonstrated a reduction in epileptiform discharges and seizures in patients living with drug-resistant (medications are not effective) epilepsy after listening to specific music. it is believed to be the first study to examine the effect of daily, self-administered musical stimuli in reduction of epileptiform event detections over days to weeks. the study will enroll a cohort of patients already implanted with neuropace responsive neurostimulator (rns) device to treat their epilepsy. this device uses continuous, outpatient electrocorticographic recording data to provide immediate (or 'responsive') closed loop neurostimulation. primary hypothesis is that patients with drug resistant epilepsy, implanted with rns, will have fewer epileptic activity episodes (rns 'long episodes') during the weeks of experimental music intervention. the study team expect to see improvement with daily listening to specific music intervention (experimental, music a), but not with active comparators (music b or c). the effect, if any, of music intervention is expected to last at least one week after the intervention period (block) (for each music piece) ends. secondary hypothesis is that the music listening every day will be associated with improved self-report of mood, quality of life, and self-reported measures of cognition. the study team suspects that this effect will not be limited to just one specific musical piece. this study will also look to determine the feasibility of an at-home, self-administered auditory intervention in drug resistant epilepsy.

Eligibility criteria:
inclusion criteria: * adults with medication-refractory focal epilepsy who have undergone rns implantation at least six months prior and are in the judgement of the treating physician on a stable rns regimen in terms of stimulation * willing to attend all study visits and complete all required study procedures * access to private or public wireless data service at regular intervals * access to personal mobile device exclusion criteria: * documentation of a musicogenic, or auditory-triggered focal seizure semiology * participant is unable to reasonably participate in study tasks as determined by the investigator * inability to obtain informed consent from the patient or legally authorized representative

Keywords: music epilepsy responsive neurostimulation interictal discharge
cardiovascular diseases in hiv-infected subjects (hiv-heart study)

Conditions: Detection of Frequency, Severity and Progression of Cardiovascular Diseases in Patients With HIV-infection.; Effect on Cardiovascular Risk and Life Quality by Age, Gender, Classic Cardiovascular Risk Factors,; HIV-specific Cardiovascular Risk Factors, Cardiovascular Medication, Antiretroviral Medication

Summary: human immunodeficiency virus (hiv) infection has been associated with a variety of cardiovascular diseases. even most industrialised countries exhibit a growing and aging population of hiv-infected patients in the majority treated with antiretroviral drugs, the investigators still do not know much about the impact of cardiovascular diseases in this group of patients. the present study is an ongoing trial that was conducted as a prospective and multicentre survey, being schemed to analyse the frequency and clinical course of cardiac disorders in hiv-infected patients.


Eligibility criteria:
inclusion criteria: * age \> 18 years * known hiv-infection * outpatients * written informed consent exclusion criteria: ● acute cardiovascular disease or unstable hemodynamic status in the three weeks before inclusion • pregnancy

Keywords: cardiac diseases • hiv-infection • aids • antiretroviral therapy
efficacy, safety and tolerability of pf-06743649 in gout subjects.

Conditions: Gout

Summary: the purpose of the study is to assess the effect of pf-06743649 in lowering serum uric acid in subjects suffering from gout following 14 days of dosing, as well as assessing safety and tolerability.


Eligibility criteria:
inclusion criteria: * subject meets the diagnosis of gout as per the american rheumatism association criteria for the classification of acute arthritis of primary gout. * subjects taking urate lowering therapy at the time of screening must be willing to discontinue their prior urate lowering therapy from the time of screening visit 1 until completion of the study period day 16. * subjects taking urate lowering therapy at the time of screening must have a serum urate level of \>= 8.0 mg/dl at time of the second screening visit. * subjects not taking urate lowering therapy at the time of screening must have a serum urate level of \>= 8.0 mg/dl at both screening visits 1 and 2. exclusion criteria: * positive medical history or current evidence of medical or psychiatric condition/disease, or ecg or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study. * chronic kidney disease classified as moderate or severe (clinical practice guideline, national kidney foundation)12; with gfr \< 60 ml/min/1.73m2 calculated by the cockcroft-gault equation. * subjects with current tophaceous gout. * gout flare that has not resolved for at least 2 weeks prior to randomization.

Keywords: hyperuricemia gout serum uric acid
should we use oral valacyclovir in acute herpetic gingivostomatitis in children?

Conditions: Herpetic Gingivostomatitis

Summary: primary herpetic gingivostomatitis is a frequent problem in pediatrics. complications of this are dehydration, pain and hospitalisation. the objective of this randomized controlled trial is to assess the clinical efficacy of oral valacyclovir to decrease the duration of symptoms associated with acute herpes gingivostomatitis in children. this study will involve 80 children aged 1 to 8 years old to receive weight adjusted doses of valacyclovir for 7 days. the primary outcome measure will be the duration (in days) of feeding and/or drinking difficulties.


Eligibility criteria:
inclusion criteria are : * children from 10 to 28 kg of weight. the inclusion of participants is based on weight for practical/feasibility reasons because the study medication will be provided in tablet format. the lower limit of 10 kg is to limit to three strata of weight and limit costs engendered by the preparation of medication. * clinical diagnosis of herpetic gingivostomatitis according to the treating physician. this is described by the presence of: * fever (\>38.5° rectal, \>38° oral) and * vesicular or ulcerative lesions located in the anterior of the mouth * associated or not with perioral vesicular lesions visiting the emergency department within the first 96 hours of the disease begin. exclusion criteria are : * duration of fever \> 4 days * hospitalised patients * immunocompromised patients * patients with known hypersensitivity to valacyclovir * patients with renal failure * children with complete incapacity of oral treatment intake * unable to be contacted for phone follow-up
pola-r2 in newly diagnosed non-fit elderly dlbcl patients

Conditions: Diffuse Large B Cell Lymphoma

Summary: this is a prospective, single-arm, phase ii study, and the purpose of this study is to evaluate the efficacy and safety of pola-r2 regimen in newly diagnosed elderly diffuse large b cell lymphoma classified into un-fit or frail group by comprehensive geriatric assessment(cga).

in this prospective study, all the eligible patients will be given pola-r2 regimen(polatuzumab vedotin 1.8 mg/kg ivgtt d1, rituximab375 mg/m2 ivgtt d1, lenalidomide 25mg po d1-14, one cycle every 21 days). an interim evaluation will be performed after 4 cycles, the patients who achieve cr or pr will receive another 4 cycles of pola-r2. the patients with stable disease (sd) or progressed disease (pd) will withdraw from the trial and receive salvage regimens.

Eligibility criteria:
inclusion criteria: * the patient volunteered to participate in the study and signed the informed consent * histopathologically confirmed dlbcl and treatment naive(corticosteroids alone is not considered as a line of treatment) * age≥ 70 years old, and was un-fit or frail according to comprehensive geriatric assessment * adequate organ function and adequate bone marrow reserve exclusion criteria: * coexisting malignancy other than lymphoma * active hbv infection * any instability of systemic disease, including but not limited to active infection (except local infection), severe cardiac, liver, kidney, or metabolic disease need therapy
surgeon-patient communication: a randomized controlled trial evaluating the impact of an orthopaedic related smoking cessation discussion after fracture surgery

Conditions: Orthopaedic Decision Making

Summary: in this study, the investigators are interested in evaluating the impact of an orthopaedic related smoking cessation discussion after fracture surgery.


Eligibility criteria:
inclusion criteria: * patients 18 year old or older, * daily smoker * inpatient post fracture operation, * patient that have never received an orthopaedic related smoking cessation discussion exclusion criteria: * younger than 18, * patients unable to provide consent * patients that suffer from auditory/visual/mental disability requiring another individual as a decision-maker
comparison of difference histamine concentration (1, 5 and 10 mg/ml) for skin prick test positive control

Conditions: Immediate Hypersensitivity

Summary: skin prick test (spt) was used for diagnostic test for type 1 hypersensitivity. the efficacy and safety of spt were proved. the positive control of spt is histamine. in thailand, the most common concentration of histamine for spt is 10 mg/ml. however, in some practice they use other concentration (1, 2.5 mg/ml). this study will find the proper concentration of histamine for positive control use in spt.

appropriate concentration of histamine positive control is important in interpretation the result of skin prick test.

Eligibility criteria:
inclusion criteria: * parcitipate person who attented allergy clinic, ent clinic * legible in thai language exclusion criteria: * patient cannot withhold antihistamine drug * pragnancy and lactation mother * comorbid disease such as cardiac disease, liver, renal, hypertension and severe asthma
selegiline transdermal system for the treatment of cocaine dependence - 1

Conditions: Cocaine-Related Disorders

Summary: the purpose of this study is to evaluate the selegiline transdermal system for the treatment of cocaine dependence.

the study objectives are to assess the efficacy and safety of the selegiline transdermal system (sts) in reducing cocaine use in subjects with cocaine dependence. it is hypothesized that selegiline treatment compared to placebo, will be associated with fewer days of cocaine use as assessed by self-report confirmed with urine assays for benzoylecgonine (be).

Eligibility criteria:
inclusion criteria: * male/female * at least 18 years of age * dsm-4 diagnosis of cocaine dependence * ability to understand and provide written consent * female subjects must use acceptable birth control exclusion criteria: - additional criteria available during the screening process at the site.

Keywords: cocaine dependence
efficacy and safety of oxaliplatin combined with capecitabine as neoadjuvant chemotherapy for locally advanced colon cancer patients

Conditions: Colorectal Cancer

Summary: the study aims to identify the efficacy and safety of capecitabine plus oxaliplatin (xelox) in patients with local advanced colorectal cancer.


Eligibility criteria:
inclusion criteria: 1. performance status (ecog) 0\~2 2. histologically confirmed colon cancer. 3. no prior treatment 4. ct-defined t4 or lymph node-positive colon cancer 5. neutrophils ≥ 1.5 x 109/l, platelets ≥ 100 x 109/l, and hemoglobin ≥ 8 g/dl bilirubin level ≤ 1.0 x uln 6. ast and alt \< 1.5 x uln 7. serum creatinine ≤ 1.0 x uln 8. life expectancy of ≥ 3 months 9. signed written informed consent exclusion criteria: 1. final stage with cancer cachexia 2. allergy for capecitabine or oxaliplatin 3. any evidence of extrahepatic metastases and/or primary tumor recurrence 4. severe organ failures or diseases, including: clinically relevant coronary disease, cardiovascular disorder or myocardial infarction within 12 months before study entry, severe psychiatric illness, severe infection and dic

Keywords: neoajuvant chemotherapy
to determine the therapeutic effect of the music glove and conventional hand exercises to subacute stroke patients

Conditions: Cerebrovascular Accident

Summary: the investigators are trying to determine the therapeutic effect of the music glove and conventional hand exercise program to the subacute stroke patients. all participants will be randomized into two groups: ab and ba. they will all exercise at least 3 times a week for 3 weeks with a minimal 3 hours exercise time per week. participants will receive the other intervention at 3-month post stroke date. clinical evaluations will be performed at baseline, post therapy after first intervention, 3-week post intervention follow up, 3-month post stroke, post therapy after second intervention, 3-week post second intervention follow up, and 6-month post stroke follow up visits.


Eligibility criteria:
inclusion criteria: * history of a single stroke at least 1 week prior to enrollment * upper extremity weakness measured on a standard clinical scale * no active major psychiatric problems, or neurological/orthopedic problems affecting the stroke affected upper extremity * no active major neurological disease other than the stroke * absence of pain in the affected upper extremity exclusion criteria: * severe tone at the affected upper extremity as measured on a standard clinical scale * severe aphasia as measured on a standard clinical scale * severe reduced level of consciousness * severe sensory/proprioception deficit at the affected upper extremity as measured on a standard clinical scale * currently pregnant * difficulty in understanding or complying with instructions given by the experimenter * inability to perform the experimental task that will be studied * increased pain with movement of the affected upper extremity

Keywords: stroke
chemotherapy, filgrastim, and radiation therapy in treating patients with primary central nervous system lymphoma

Conditions: Lymphoma

Summary: rationale: drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. radiation therapy uses high-energy x-rays to damage cancer cells. combining chemotherapy with radiation therapy may kill more cancer cells. colony-stimulating factors such as filgrastim allow doctors to give higher doses of chemotherapy drugs to kill more cancer cells. purpose: phase ii trial to study the effectiveness of lomustine, procarbazine, filgrastim, and radiation therapy in treating patients who have primary central nervous system lymphoma.

objectives: i. determine response rate, response duration, and survival of patients with aids-related or immunocompetent primary central nervous system lymphoma after treatment with oral lomustine and procarbazine, filgrastim (g-csf), and radiotherapy. ii. determine toxicity of this combined modality in these patients. iii. determine quality of life of these patients. outline: patients are stratified by cd4 count (50/mm3 and under vs greater than 50/mm3). patients receive oral lomustine on day 1 and oral procarbazine on days 1-10 and days 22-31. filgrastim (g-csf) is administered subcutaneously daily on days 12-21 and days 33-42, until absolute neutrophil counts recover. patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy. patients with a partial response, stable disease, or disease progression after 6 weeks proceed to radiotherapy without receiving a second course of chemotherapy. whole brain radiotherapy is administered daily for 28 days beginning 1-3 weeks following chemotherapy. quality of life is assessed prior to therapy, at 3 and 6 weeks, and then every 2 months following radiotherapy. patients are followed every 2 months until death. projected accrual: approximately 16 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically proven aids-related non-hodgkin's lymphoma of the cns or non aids-related,non-hodgkin's lymphoma of cns also eligible, if not eligible for higher priority clinical trial patient characteristics: age: 0-120 performance status: ecog 0-2 life expectancy: at least 6 weeks hematopoietic: wbc at least 1500/ mm3 platelets at least 50,000/mm3 hepatic: serum bilirubin no greater than 3.0 mg/dl renal: serum creatinine no greater than 3.0 mg/dl cardiovascular: pulmonary: other: active infection(s) allowed if drug receiving treatment no zidovudine during combined modality chemotherapy and radition negative csf cytology prior concurrent therapy: biologic therapy: chemotherapy: no prior chemotherapy endocrine therapy: steroids may be used concurrently. doses should be as low as possible. increases in steroids above study's upper limit will result in patient going off study. radiotherapy: no prior radiotherapy surgery: prior surgical debulking allowed

Keywords: primary central nervous system lymphoma aids-related primary cns lymphoma
tailored radiofrequency ablation of uterine myomas

Conditions: Uterine Fibroids

Summary: to perform the use of radiofrequency myolysis (rfm) for the treatment of intra-uterine fibroids through less invasive access by combining trans-vaginal ultrasound, hysteroscopy and laparoscopy

given that the rf ablation of solid tumors of the liver and other organs is successfully used as a usual approach, the investigators have decided to transfer this technology to an original treatment of uterine fibroids. the access to each individual fibroid was determined considering passage of the needle towards its centre through only compromised tissue and by the shortest possible route by combining trans-vaginal ultrasound, hysteroscopy and laparoscopy. to optimize radiofrequency myolysis, in fact, the investigators decided to improve the procedure by inserting three innovative elements: application of a virtual needle tracking system to follow the rf electrode during the ablation session, real-time monitoring of rf ablation by contrast-enhanced ultrasound and systematic biopsy of the lesions before electro-coagulation.

Eligibility criteria:
"inclusion criteria": * women who had symptomatic myomas with diameters ranging between 1.2 and 7.7 cm. - patients who had declined hysterectomy or laparoscopic myomectomy * submucosal fibroids with intramural extension ≥50% * intramural fibroids (figo g3 / g4 types) * subserosal fibroids (figo g5 / g6 types) "exclusion criteria": * women with intracavitary (figo g0 / g1 types) or subserosal-pedunculated fibroids / (figo g7 types) * genital malignancy * cervical dysplasias * pelvic infection / adhesions * severe systemic diseases * pregnancy * deeply infiltrating endometriosis * patients who took gonadotropin-releasing hormone therapy or acetate ulipristal within 6 months
effect of latanoprost on optic nerve perfusion

Conditions: Treatment Outcome

Summary: 46 eyes of 23 patients have been treated with topical latanoprost 0.005 %. visual field was performed on all eyes. nflt was measured using oct. radial peripapillary capillary (rpc) vascular density was measured using octa . mean ocular perfusion pressure (mopp), and rpc vascular density were measured before and after treatment by 2-3 months

all patients had bilateral primary open angle glaucoma diagnosed by increased iop, visual field changes, and defective nerve fiber layer thickness (nflt) on oct examination. all patients treated with topical latanoprost 0.005% (xalatantm, 2.5 ml eye drops, pfizer) inclusion criteria: age \&gt; 20 years, newly diagnosed patients with poag. the exclusion criteria included optic nerve lesions other than glaucomatous changes, all patients completed their ophthalmic examination to detect bcva, cycloplegic refraction, and anterior segment examination , iop measuring by applanation tonometer, and indirect ophthalmoscope fundus examination. visual field testing. the thickness of nfl around the disc was evaluated using spectral domain optical coherence tomography (oct) optovue octa was used to quantify the density of the radial peripapillary capillary (rpc) vessels. this study employed software to quantify the capillary (microvasculature) density in both the entire image and in the peripapillary region specifically the superior, nasal, inferior, and temporal quadrants. the mean arterial blood pressure (map) was determined by adding the diastolic blood pressure (dbp) to one third of the difference between systolic blood pressure and the diastolic blood pressure. all eyes were treated with topical latanoprost 0.005% (xalatantm, 2.5 ml eye drops, pfizer) with dose of one drop at bedtime. iop, mopp, nflt, and rpc vascular density were measured before the beginning of treatment and 1 and 3 months after treatment.

Eligibility criteria:
inclusion criteria: poag with no past ocular surgery or laser retinal treatment. no previous anti-glaucoma medications exclusion criteria: * optic nerve lesions other than glaucoma

Keywords: open angle glaucoma octa rnfl
the effect of the hyperinsulinemic normoglycemic clamp on myocardial function and utilization of glucose

Conditions: Hyperglycemia; Aortic Valve Replacement; Aortic Stenosis; Cardiac Surgery

Summary: the overall research plan is to test the hypothesis that intraoperative treatment of hyperinsulinemic normoglycemic clamp (hnc) in cardiac surgical patients improves myocardial function and short-term outcomes compared with standard glucose management.

specific aim #1:to determine whether intraoperative use of hnc affords cardioprotective benefits measured by improved echocardiographic measures of myocardial function, serum markers of cardiomyocyte injury, and hemodynamic indices measured immediately (at end of surgery) and during the short-term (initial hospitalization).

Eligibility criteria:
inclusion criteria: * age 40 - 84 years old, aortic stenosis, scheduled for aortic valve replacement. exclusion criteria: * poor quality echocardiographic images unsuitable for analysis * off -pump surgical procedure * anticipated deep hypothermic circulatory arrest * any contraindications to transesophageal echocardiogram (tee) or other proposed intervention * unable to give written informed consent (non-english speaking, vulnerable patients, etc.)

Keywords: hyperglycemia open heart surgery bypass